Hormone blocker plus targeted drug shows promise against tough uterine cancer
NCT ID NCT07634601
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether combining elacestrant, a drug that lowers estrogen, with everolimus, which stops cancer cells from growing and cuts their blood supply, can control advanced or recurrent ER+ endometrial cancer. About 50 adults whose cancer has returned or spread will take both pills. The study measures how long the cancer stays under control and whether the combination shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- elacestrant and everolimus
- What this could lead to
- If successful, this combination could offer a new oral treatment option for people with advanced ER+ endometrial cancer that has returned or spread.
- What could go wrong
- This is a phase II trial with only 50 participants, so results may not apply to all patients. The drugs may cause side effects like mouth sores, lung inflammation, or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug TJ037130 takes aim at advanced solid tumors
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- Cancer drug combo tested for rare gene mutation – but trial stopped early
- New drug duo shows promise for Tough-to-Treat endometrial cancer
- New pill shows promise for Hard-to-Treat uterine cancer
- Custom-Made cancer vaccine shows promise in advanced tumors